• Explore /
  • Poster
  • / Induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases: Results of a randomized phase II A-PLUS trial.

Induction bevacizumab, etoposide and cisplatin followed by whole brain radiotherapy (WBRT) versus WBRT alone in breast cancer with untreated brain metastases: Results of a randomized phase II A-PLUS trial.

Abstract Poster

Authors

null

Yen-Shen Lu

National Taiwan University Hospital, Taipei, Taiwan

Yen-Shen Lu , Ming-Shen Dai , Ling-Ming Tseng , Shin-Cheh Chen , Wei-Wu Tom Chen , Tsu-Yi Chao , Ta-Chung Chao , Yuan-Ching Chang , Chang-Fang Chiu , Chien-Ting Liu , Chingh-Hung Lin , Chun-Yu Liu , Ya-Fang Chen , Twan Ying Chang , Jyh-Cherng Yu , Kun-Ming Rau , Yao-yu Hsieh , Shih-Che Shen , Shu-Min Huang , Ann-Lii Cheng

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Other Breast Cancer Subtypes

Clinical Trial Registration Number

NCT02185352

Citation

J Clin Oncol 38: 2020 (suppl; abstr 1082)

DOI

10.1200/JCO.2020.38.15_suppl.1082

Abstract #

1082

Poster Bd #

167

Abstract Disclosures

Similar Posters

First Author: Yen-Shen Lu

First Author: Dawei Chen

Poster

2024 ASCO Genitourinary Cancers Symposium

Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.

Preliminary efficacy and safety results from ReBirth: A phase II study of risk-based bladder-sparing therapy for MIBC.

First Author: Yijun Shen

First Author: Jianqing Zhu